Results 201 to 210 of about 104,869 (316)

Investigation of the Efficacy and Safety of TO‐208 in Patients 2 Years of Age or Older With Molluscum Contagiosum in Japan: A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Study (208‐3‐1) and Its Open‐Label Extension

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Molluscum contagiosum (MC) is a common viral skin infection in children. In the two Phase 3 Cantharidin Application in Molluscum Patients [CAMP‐1 and CAMP‐2] studies, cantharidin, a drug‐device combination containing cantharidin (0.7%), a topical vesicant, was significantly superior to placebo in achieving complete clearance of MC lesions at ...
Takafumi Kadono   +9 more
wiley   +1 more source

Classification of Itch Patterns and Sentiment Analysis in Patients With Atopic Dermatitis: Clustering Analysis of Patient‐Reported Data

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD), a prevalent inflammatory skin disease, significantly impairs quality of life. Pruritus manifests variably, complicating its classification and management. This study analyzed real‐world, self‐reported data from Atopiyo, Japan's largest AD smartphone application (October 2021–October 2024), to explore itch patterns ...
Atsushi Otsuka   +7 more
wiley   +1 more source

Itch Is Now Made Visible: Advances in fMRI and Its Relevance to Dermatology. [PDF]

open access: yesSkin (Milwood)
Schandua H   +6 more
europepmc   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Expanding the Use of PAVA Spray in Young Offender Institutions: The King (on the application of The Howard League for Penal Reform) v The Secretary of State for Justice

open access: yesThe Modern Law Review, EarlyView.
This case note critically examines the January 2026 High Court judgment in The King (on the application of The Howard League for Penal Reform) v The Secretary of State for Justice which dismissed a judicial review challenging the expansion of the use of PAVA spray in Young Offender Institutions (YOIs) in England.
Raymond Arthur
wiley   +1 more source

Effectiveness of tobacco cessation interventions in adolescents: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Globally, around 11% of adolescents aged 13–15 years use tobacco products, and over one‐third of users are estimated to be tobacco dependent. Interventions to support adolescents to quit smoking are recommended to mitigate adverse health effects.
Courtney Barnes   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy